Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study

详细信息    查看全文

• 作者：Erin X. Wei ; MD^a ; ^{wei.erin@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Abrar A. Qureshi ; MD ; MPH^b ; ^d ; ^e ; Jiali Han ; PhD^b ; ^f ; ^g ; Tricia Y. Li ; MD ; MS^b ; Eunyoung Cho ; ScD^b ; ^d ; ^e ; Jennifer Y. Lin ; MD^c ; Wen-Qing Li ; PhD^d ; ^e
• 关键词：age ; anatomic sites ; epidemiology ; gender ; incidence ; invasive malignant melanoma ; lentigo maligna ; melanoma ; melanoma in situ ; melanoma screening ; occupational cohorts
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：75
• 期：4
• 页码：698-705
• 全文大小：775 K

文摘

The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features.

Objective

We sought to determine trends in diagnosis and clinical features of MIS.

Methods

Incident cases of melanoma were collected prospectively from the Nurses' Health Study (1976-2010) and Health Professionals Follow-up Study (1986-2010).

Results

MIS incidence increased from 2 to 42 per 100,000 person-year among women, and from 11 to 73 per 100,000 person-year among men, exceeding the rate of increase of invasive melanomas. Melanoma mortality initially increased during the follow-up period then plateaued. Men were more likely than women to develop in situ melanomas on the upper half of the body (P < .001). Invasive melanomas were diagnosed at a younger age than MIS (P < .001), and were more likely to be found on the lower extremities than MIS (P < .001).

Limitations

This is a strictly descriptive study without examination into mechanisms.

Conclusion

We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.